SVB Leerink

Silverback Therapeutics Inc (NASDAQ: SBTX) recently raised $277.7 million by selling 13.225 million shares in an initial public offering that were priced at $21 each. The Silverback Analyst: SVB Leerink analyst Daina Graybosch initiated coverage of Silverback Therapeutics with an Outperform...

Kinnate Biopharma Inc (NASDAQ: KNTE), which focuses on developing small-molecule kinase inhibitors for difficult-to-treat, genomically-defined cancers, recently raised $276 million in gross proceeds in an initial public offering priced at $20 per share. The Kinnate Biopharma Analyst:...

Moderna Inc's (NASDAQ: MRNA) coronavirus vaccine candidate, mRNA-1273, got FDA panel backing, in line with expectations, and is likely to be accorded emergency use authorization any time now. An Unsurprising Decision: The 20-0 vote, with one abstention, in favor of issuing an EUA for mRNA-1273...

Pfizer Inc. (NYSE: PFE) and BioNTech SE's – ADR (NASDAQ: BNTX) coronavirus vaccine candidate passed the Adcom test, with the FDA panel voting 17-4 in favor of its risk-benefit profile in individuals 16 and older.  Here's SVB Leerink analyst Geoffrey Porges' take on the...

AstraZeneca plc (NASDAQ: AZN) announced Monday interim Phase 3 data for its coronavirus vaccine candidate AZD1222 from studies conducted in the U.K. and Brazil, showing efficacy ranging between 62% and 90%. The AstraZeneca Analysts: SVB Leerink analyst Geoffrey Porges has an Outperform rating on...

Moderna Inc (NASDAQ: MRNA) announced Monday positive efficacy data from the first interim analysis of the Phase 3 COVE study of its investigational coronavirus vaccine mRNA-1273. The Moderna Analysts: SVB Leerink analyst Mani Foroohar maintained an Underperform rating on Moderna. Needham analyst...

Pfizer Inc. (NYSE: PFE) reported Monday with strong Phase 3 interim efficacy data for its coronavirus vaccine candidate. The Pfizer Analysts: Morgan Stanley analyst David Risinger has an Equal-weight rating on Pfizer with a $42 price target.  SVB Leerink analyst Geoffrey Porges...

Moderna Inc (NASDAQ: MRNA) shares were advancing strongly Monday after a rival vaccine developed by Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX) showed efficacy in a late-stage study. High Bar For Moderna To Clear: The 90% vaccine efficacy demonstrated by Pfizer and...

Biogen Inc (NASDAQ: BIIB) shares are retreating sharply after an Adcom committee recommended against approval of its investigational Alzheimer's drug aducanumab. Despite the setback, an analyst at SVB Leerink said aducanumab could still successfully clear the final FDA hurdle. The Biogen...

Moderna Inc (NASDAQ: MRNA) reported mixed quarterly results Thursday and suggested an interim efficacy readout from the Phase 3 study is likely in November. The Moderna Bull Case: Moderna's vaccine timeline is intact, according to Needham analyst Alan Carr, who rates the shares a Buy...

Shares of cancer screening and diagnostics company EXACT Sciences Corporation (NASDAQ: EXAS) were rallying to a record high Tuesday after it announced two M&A transactions and third-quarter results. Exact Sciences Strikes 2 Deals: Madison, Wisconsin-based Exact Sciences said it has...

Biogen Inc (NASDAQ: BIIB) reported fairly solid third-quarter results Wednesday, sending its shares higher.  Against this backdrop, an analyst at SVB Leerink said the key to outperformance for the company is a positive regulatory ruling on its controversial Alzheimer's treatment candidate...

The mRNA coronavirus vaccine in development by Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX) is poised for an emergency use authorization application, according to SVB Leerink.  The Pfizer Analyst: Geoffrey Porges has a Market Perform rating on Pfizer shares. The Pfizer...

The coronavirus vaccine race has two likely winners that have surged ahead in a crowded field, according to an SVB Leerink analyst. Pfizer, Moderna In The Lead: It now appears that Moderna Inc (NASDAQ: MRNA) and Pfizer Inc. (NYSE: PFE), along with its German partner BioNTech SE – ADR (...

Moderna Inc (NASDAQ: MRNA) is one of the frontrunners in a crowded race to develop a vaccine against the novel coronavirus. Despite Moderna's strong positioning, an analyst at SVB Leerink said he harbors some concerns over the company's vaccine program. The Moderna Analyst: Mani...